G
Glenmark Life Sciences Ltd
NSE:GLS
Glenmark Life Sciences Ltd
NSE:GLS
Price:
1 100.6
INR
-2.89%
Market Closed
Market Cap:
₹134.9B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
G
|
Glenmark Life Sciences Ltd
NSE:GLS
|
IN |
|
Geospace Technologies Corp
NASDAQ:GEOS
|
US |
|
Anhui Conch Cement Co Ltd
SSE:600585
|
CN |
|
Lockheed Martin Corp
NYSE:LMT
|
US |
|
N
|
Nanotech Indonesia Global Tbk PT
IDX:NANO
|
ID |
|
A
|
AMP Ltd
NZX:AMP
|
AU |
|
SABIC Agri-Nutrients Company SJSC
SAU:2020
|
SA |
|
Finwise Bancorp
NASDAQ:FINW
|
US |
|
Vaisala Oyj
OTC:VAIAF
|
FI |
|
Anghami Inc
NASDAQ:ANGH
|
AE |
Balance Sheet
Balance Sheet Decomposition
Glenmark Life Sciences Ltd
Glenmark Life Sciences Ltd
Balance Sheet Decomposition is not available for
Glenmark Life Sciences Ltd
Glenmark Life Sciences Ltd
Balance Sheet
Glenmark Life Sciences Ltd
Glenmark Life Sciences Ltd
Currency: INR
| Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
21
|
100
|
1 156
|
5 122
|
2 838
|
3 014
|
|
| Cash |
0
|
1
|
1
|
221
|
558
|
318
|
|
| Cash Equivalents |
20
|
99
|
1 155
|
4 901
|
2 281
|
2 696
|
|
| Total Receivables |
5 176
|
7 073
|
7 268
|
7 152
|
9 183
|
9 320
|
|
| Accounts Receivables |
4 481
|
6 386
|
6 195
|
6 735
|
8 068
|
7 654
|
|
| Other Receivables |
695
|
687
|
1 073
|
417
|
1 115
|
1 665
|
|
| Inventory |
4 008
|
4 128
|
5 134
|
5 162
|
6 219
|
6 811
|
|
| Other Current Assets |
102
|
300
|
432
|
210
|
264
|
15
|
|
| Total Current Assets |
9 307
|
11 601
|
13 990
|
17 646
|
18 503
|
19 160
|
|
| PP&E Net |
5 303
|
5 498
|
5 790
|
6 763
|
8 242
|
8 962
|
|
| PP&E Gross |
5 303
|
5 498
|
5 790
|
6 763
|
8 242
|
8 962
|
|
| Accumulated Depreciation |
187
|
475
|
773
|
1 130
|
1 516
|
1 994
|
|
| Intangible Assets |
64
|
72
|
79
|
104
|
180
|
149
|
|
| Note Receivable |
0
|
0
|
12
|
0
|
13
|
123
|
|
| Long-Term Investments |
1
|
1
|
86
|
56
|
1
|
1
|
|
| Other Long-Term Assets |
79
|
84
|
14
|
141
|
82
|
110
|
|
| Total Assets |
14 754
N/A
|
17 256
+17%
|
19 971
+16%
|
24 710
+24%
|
27 021
+9%
|
28 504
+5%
|
|
| Liabilities | |||||||
| Accounts Payable |
1 874
|
2 035
|
2 226
|
3 077
|
4 272
|
3 687
|
|
| Accrued Liabilities |
96
|
121
|
204
|
421
|
84
|
284
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
17
|
23
|
24
|
|
| Other Current Liabilities |
11 834
|
10 919
|
9 784
|
325
|
587
|
393
|
|
| Total Current Liabilities |
13 804
|
13 075
|
12 214
|
3 840
|
4 965
|
4 388
|
|
| Long-Term Debt |
0
|
0
|
0
|
12
|
171
|
148
|
|
| Deferred Income Tax |
69
|
164
|
229
|
315
|
424
|
488
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
79
|
158
|
|
| Total Liabilities |
13 873
N/A
|
13 239
-5%
|
12 443
-6%
|
4 167
-67%
|
5 639
+35%
|
5 181
-8%
|
|
| Equity | |||||||
| Common Stock |
20
|
20
|
20
|
245
|
245
|
245
|
|
| Retained Earnings |
862
|
3 997
|
7 508
|
10 249
|
11 087
|
13 029
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
10 050
|
10 050
|
10 050
|
|
| Total Equity |
881
N/A
|
4 017
+356%
|
7 527
+87%
|
20 543
+173%
|
21 382
+4%
|
23 323
+9%
|
|
| Total Liabilities & Equity |
14 754
N/A
|
17 256
+17%
|
19 971
+16%
|
24 710
+24%
|
27 021
+9%
|
28 504
+5%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
123
|
123
|
123
|
123
|
123
|
123
|
|
Switch to:
Switch to:
See Also
Discover More
